Portuguese
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

hepatitis b/protease

O link é salvo na área de transferência
Página 1 a partir de 20 resultados

Monovalent Recombinant COVID19 Vaccine

Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
Human infections with zoonotic coronaviruses including severe acute respiratory syndrome coronavirus (SARS CoV), Middle East respiratory syndrome-associated coronavirus (MERS CoV) and now 2019 SARS-CoV-2, all pose major human public health threats with high case fatality rates. The outbreak of

Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon

Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
Chronic delta hepatitis is a serious form of chronic liver disease caused by infection with the hepatitis D virus (HDV), a small RNA virus that requires farnesylation of its major structural protein (HDV antigen) for replication. Based on previous and ongoing clinical trials demonstrating

Impact of Different Integrase Inhibitor Based Regimen on Immune Activation Among HIV naïve Patient (INTATTI)

Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
INTRODUCTION AND BACKGROUND Combination antiretroviral therapy (cART) controls HIV-1 plasma viral load in most patients, leading to a reduction in morbidity and mortality [Egger M, BMJ 1997; Detels R, JAMA 1998]. Despite efficient treatment persistent low-level viral replication and immune
The treatment of chronic Hepatitis C with combination directly acting antiviral agents (DAAs) represents a dramatic improvement over previous therapies in safety, tolerability and efficacy, but these therapies are not universally effective. Some patients fail to achieve sustained virologic response

Observational, Retrospective Analysis in HIV-1 Infected Patients. (ORASWIRAL)

Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
Adult, male and female HIV-1 infected subjects, who started an antiretroviral regimen of RALTEGRAVIR plus ABACAVIR and LAMIVUDINE after a different antiretroviral regimen. Subject Selection: Inclusion Criteria All consecutive patients fulfilling the following inclusion criteria will be considered: -

Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir

Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
Chronic delta hepatitis is a serious form of chronic liver disease caused by infection with the hepatitis D virus (HDV), a small RNA virus that requires farnesylation of its major structural protein (HDV antigen) for replication. We propose to treat 21 adult patients with chronic delta hepatitis

Boceprevir-based Therapy to Rescue HCV Genotype 1/HBV Infected Patients Refractory to Combination Therapy

Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
Liver disease, especially viral hepatitis, is an important public health issue, which frequent leads to liver cirrhosis, hepatocellular carcinoma (HCC) and liver-related death. Around 340 to 400 million persons are infected with hepatitis B virus (HBV) and 130 to 210 million persons are infected
In the last years, various clinical trials and studies have evaluated the incidence of hepatic toxicity (HT) associated with the commonly used antiretroviral drugs in the HIV/hepatitis C virus (HCV)-infected population. Unfortunately, clinical trials that compared hepatic safety of these

A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure

Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
A5288 was an open-label phase IV, prospective interventional, strategy study in resource-limited settings (RLS) for HIV-1 infected participants with triple-class experience or resistance to nucleoside reverse transcriptase inhibitors (NRTIs), non-NRTIs (NNRTIs), and protease inhibitors (PIs) and who
Raltegravir is an HIV-1 integrase inhibitor that is currently licensed for use in treatment-experienced HIV-1 patients and recently approved for use in treatment-naïve patients. Recent data has shown that the virologic response in patients on raltegravir with no history of antiretroviral treatment

The St. Marys and The Mater Switch Study

Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
To assess the safety, changes in platelet reactivity, plasma cardiac biomarkers and metabolic parameters in HIV 1 infected subjects undergoing a switch in ART from a nucleoside containing regimen which includes abacavir and / or didanosine to a maraviroc containing regimen. 40 HIV-1 infected

An Interaction Study to Assess Drug Levels in Fasting Healthy Adult Subjects

Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
This randomized, open-label, six-arm, three-period drug interaction study will recruit 48 healthy volunteers so as to obtain a minimum of 36 evaluable subjects at a single study center in the U.S. The study will have a screening visit, 3 treatment visits for pharmacokinetics (PK) sampling and a
Background: Human papilloma virus (HPV) is one of the most common sexually transmitted diseases and a significant cause of cutaneous genital warts and anogenital cancer. Infection with high-risk, oncogenic HPV types, most commonly types 16 and 18, is associated with low and high-grade cervical

An Interaction Study to Assess Drug Levels in Healthy Adult Subjects

Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
This randomized, open-label, six-arm, three-period drug interaction study will recruit 48 healthy volunteers so as to obtain a minimum of 36 evaluable subjects at a single study center in the U.S. The study will have a screening visit, 3 treatment visits for PK sampling and a follow-up visit. The

An Interaction Study to Assess Drug Levels in Healthy Adult Subjects

Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
This randomized, open-label, six-arm, three-period drug interaction study will recruit 48 healthy volunteers so as to obtain a minimum of 36 evaluable subjects at a single study center in the U.S. The study will have a screening visit, 3 treatment visits for pharmacokinetics (PK) sampling and a
Junte-se à nossa
página do facebook

O mais completo banco de dados de ervas medicinais apoiado pela ciência

  • Funciona em 55 idiomas
  • Curas herbais apoiadas pela ciência
  • Reconhecimento de ervas por imagem
  • Mapa GPS interativo - marcar ervas no local (em breve)
  • Leia publicações científicas relacionadas à sua pesquisa
  • Pesquise ervas medicinais por seus efeitos
  • Organize seus interesses e mantenha-se atualizado com as notícias de pesquisa, testes clínicos e patentes

Digite um sintoma ou doença e leia sobre ervas que podem ajudar, digite uma erva e veja as doenças e sintomas contra os quais ela é usada.
* Todas as informações são baseadas em pesquisas científicas publicadas

Google Play badgeApp Store badge